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Mucosal associated invariant T (MAIT) cells are an innate-like T cell subset prevalent in
humans and distributed throughout the blood and mucosal sites. Human MAIT cells are
defined by the expression of the semi-invariant TCRα chain TRAV1-2/TRAJ12/20/33
and are restricted by the non-polymorphic major histocompatibility complex (MHC)
class I-like molecule, MHC-related protein 1, MR1. MAIT cells are activated by small
organic molecules, derived from the riboflavin biosynthesis pathway of bacteria and fungi,
presented by MR1. Traditionally, MAIT cells were thought to recognize a limited number of
antigens due to usage of an invariant TCRα chain and restriction by a non-polymorphic
MHC molecule. However, recent studies demonstrate that the TCR repertoire of MAIT
cells is more heterogeneous, suggesting there is a more diverse array of MR1 antigens
that MAIT cells can recognize. In response to infected cells, MAIT cells produce the
pro-inflammatory cytokines, IFN-γ and TNF, and are cytolytic. Studies performed in
MR1-deficient mice suggest that MAIT cells can provide anti-bacterial control within the
first few days post-infection, as well as contribute to enhanced adaptive immunity in
murine models of respiratory infections. In humans, the role of MAIT cells is unclear;
however, evidence points to interplay between MAIT cells and microbial infections,
including Mycobacterium tuberculosis. Given that MAIT cells are pro-inflammatory, serve
in early control of bacterial infections, and appear enriched at tissue sites where microbes
interface and gain access to the body, we postulate that they play an important role in
antimicrobial immune responses. In this review, we discuss the most recent studies on
the function and phenotype of MAIT cells, including their TCR diversity and antigenic
repertoire, with a focus on the contribution of human MAIT cells in the immune response
to microbial infection.
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Introduction
The immune system is conceptually divided into two general categories: innate and adaptive. Innate
immunity is considered the first line of defense and is mediated largely by epithelial cells and
phagocytes that detect and kill foreign microbes through many mechanisms, including the use of
germ-line encoded receptors, referred to as pattern recognition receptors (PRRs). PRRs allow innate
immune cells to quickly detect and respond to infections by binding to molecules associated with
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pathogens, called pathogen associated molecular patterns
(PAMPs). Adaptive immunity consists of T and B lymphocytes
that use rearranged antigen recognition receptors to detect a
wide range of antigens. The antigen recognition receptor on
T cells, the T cell receptor (TCR), recognizes foreign antigens
only when they are bound to major histocompatibility complex
(MHC) molecules, which are expressed on the cell surface of host
cells. In general, activation through the TCR results in clonal
expansion of T cells specific for a particular antigen, acquisition
of effector functions, and the development of long-lived T cells,
which provide immunological memory, resulting in long-term
protection against subsequent re-infection.
Mucosal associated invariant T (MAIT) cells, a subset of
non-classically restricted T cells, share characteristics of classical
MHC-I- and MHC-II-restricted T cells, yet have unique prop-
erties that have lead to their description as “innate-like.” Like
conventional T cells,MAIT cells undergo TCR rearrangement and
positive selection in the thymus (1–3). However, unlike conven-
tional T cells that remain naïve until antigenic-stimulation in the
periphery, MAIT cells gain effector capacity prior to exiting the
thymus (4, 5). Thus,MAIT cells have an inherent capacity to detect
and respond to infection. In addition to the acquisition of innate-
like features in the thymus, MAIT cells can expand and adapt
following egress into the circulation (5).
In stark contrast to conventional TCRαβ T cells that recog-
nize peptide antigens presented by MHC-I or MHC-II molecules,
MAIT cells become activated by small molecules presented by the
non-polymorphic MHC class I-related molecule, MR1(6). MAIT
cells function similarly to conventional CD8+ effector T cells
by secreting pro-inflammatory cytokines and cytotoxic molecules
in response to microbial infections ex vivo (7, 8). Moreover,
MAIT cells have been shown to play a role in host antibac-
terial responses in vivo (9–11). In this review, we will present
compelling evidence suggesting MAIT cells serve as sentinels of
infection at the mucosal surface, where they may (i) contribute to
immediate protection against microbes, (ii) augment induction of
adaptive immunity, and (iii) potentially provide immunological
memory.
MAIT Cells at a Glance
TRAV1-2 expressing T cells were originally described in 1993
by Porcelli et al. as a population of TCRαβ T cells, enriched
in the CD4 CD8  (double negative) T cell subset of human
blood, expressing the invariant TCRα chain TRAV1-2 paired
with TRAJ33 (Vα7.2J33) (12). The authors suggested that these
invariant TCR sequences were indicative of restriction by a non-
polymorphicMHCmolecule potentially presenting a limited fam-
ily of antigens. Tilloy et al. further described this population
of TRAV1-2 expressing T cells as a TAP-independent and β2-
microglobulin-dependent T cell subset (13). A decade after their
original description, Treiner et al. described the non-polymorphic
non-classical MHC molecule, MR1, as the antigen-presenting
molecule for TRAV1-2/TRAJ33-expressing T cells (1). Further-
more, they described these cells as being enriched at mucosal
tissues, including the small intestine, and thereby named them
MAIT T cells.
Within this seminal study, Treiner et al. presented data demon-
strating for the first time that there was a relationship between
MAIT cells and microbes. MAIT cells were found to be absent
in germ-free mice, indicating their expansion in the periphery
depended on microbial ligands (1). In 2010, MAIT cells were
shown to have a physiological role in their capacity to detect
bacteria and fungi and secrete pro-inflammatory cytokines (7,
8). Consistent with this finding was the discovery of the first
set of MR1 ligands, which were identified as small molecule
vitamin B metabolites derived from microbes (6). Cumulatively,
these studies suggested that MAIT cells could serve as innate-like
T cells in the antimicrobial immune response. This hypothesis
was supported by mouse models where deletion of MR1, and
hence MAIT cells, rendered mice more susceptible to bacterial
infections (9–11).
MAIT Cells are Antimicrobial
In 2003, Treiner et al. found that MAIT cells were absent in germ-
free mice; yet, they could be reconstituted by the oral inoculation
of single bacterial species, we now know to be MAIT-activating,
including Enterobacter cloacae or Lactobacilius acidophilus (1, 8).
By contrast, iNKT cell frequencies were unaltered in germ=free
mice (14). These data suggested that MAIT cells, but not iNKT
cells, requiredmicrobial ligands for expansion in blood and tissue.
A decade later, two simultaneous studies presented definitive
evidence that MAIT cells were reactive to antigens produced by
bacteria and fungi presented by MR1(7, 8).
The first study was predicated on the observation that a sig-
nificant proportion of CD8+ T cells from the blood of humans
who had no prior exposure toMtb could produce IFN-γ when co-
cultured overnight with dendritic cells (DCs) infected with Mtb
(15, 16). Given that responses to known protein ligands were lim-
ited to those individuals with evidence of previous infection with
Mtb, we postulated that these responses could either reflect previ-
ous exposure to antigens derived from ubiquitous environmental
mycobacteria or could be non-classically restricted T cells.
Direct demonstration of the presence of mycobacteria-reactive,
non-classically restricted CD8+ T cells came from a study of
human thymocytes, a population of antigen-inexperienced T cells
(4). In this work, Mtb-reactive CD4  thymocytes with the ability
to produce IFN-γ directly ex vivo were readily detected in all
donors tested. Furthermore, the functional capacity of these cells
was not altered in the presence of W6/32, a pan-HLA (HLA-A,
B, C) blocking antibody, suggesting that these thymocytes were
restricted by a non-classical MHC molecule.
In an effort to characterize theMHC restriction of humanMtb-
reactive CD8+ T cells, limiting dilution analysis (LDA) cloning
was used to isolate CD8+ T cell clones from the blood of either
uninfected individuals or individuals infected with Mtb (15). The
majority (64%) of the Mtb-reactive CD8+ T cell clones generated
from subjects with active TB were classically restricted T cells, as
they responded uniquely to antigen-presenting cells (APCs) from
HLA-matched donors but not those that were HLA-mismatched.
By contrast, 85% of the CD8+ T cell clones generated from
uninfected individuals with no previous exposure toMtb detected
antigen that was non-classically restricted, consistent with their
Frontiers in Immunology | www.frontiersin.org July 2015 | Volume 6 | Article 3442
Napier et al. MAIT cells in antimicrobial immunity
ability to respond to HLA-mismatched APCs. Expansion of
non-classically restricted T cells from all donors allowed for more
detailed analysis of the restricting allele. While the addition of
eitherW6/32 or anti-CD1 antibodies did not result in diminished
T cell activation, the addition of an anti-MR1 antibody resulted
in complete inhibition. Furthermore, these MR1-restricted clones
expressed the invariant TCRα chain, TRAV1-2, consistent with
their characterization as MAIT cells (7). In addition to Mtb, the
MAIT cell clones could be activated by DCs infected with bacteria
and fungi, including Salmonella enterica serovar typhimurium,
Escherichia coli, Staphylococcus aureus, Candida albicans, and
Sacchromyces cerevisiae in an MR1-dependent manner. Taken
together, these data indicated that MAIT cells were present in
humans with no previous exposure to Mtb, and that these cells
recognized cells infected with bacteria and fungi.
In a parallel study, Le Bourhis et al. also showed that puri-
fied CD3+ TRAV1-2+ CD161+ MAIT cells from humans could
be activated by monocytes infected with E. coli or Mycobac-
terium abscessus in an MR1-dependent manner (8). Using TCR-
transgenicmice expressingTRAV1TRBV6-transgenic T cells, they
demonstrated that MAIT cells were activated by DCs infected
with multiple bacterial and fungal species, including E. coli,
Pseudomonas aeruginosa, Klebsiella pneumonia, L. acidophilus,
S. aureus, and S. epidermidis, C. albicans, C. glabrata, and S.
cerevisiae. Importantly, these studies suggested that the bacteria
Listeria monocytogenes, Streptococcus group A, and Escherichia
faecalis, and as shown in both studies, all viruses tested, were not
able to activate MAIT cells (7). For the first time, these studies
demonstrated that specific microbes activated MAIT cells in an
MR1-dependent manner and proposed a role for MAIT cells in
antimicrobial immunity.
MAIT Cell Development
Mucosal associated invariant T cells, like other TCRαβ T cells,
depend on the thymus for their development (1–3). In the thy-
mus, MAIT cells undergo TCR rearrangement through somatic
recombination followed by positive selection (1–3). However,
while classically restricted T cells are positively selected on thymic
epithelial cells expressing MHC-I or MHC-II, murine MAIT
cells are selected on CD4+CD8+ double positive hematopoietic
cells that express high levels of MR1(2, 3). In humans, MR1 is
also expressed onhumanhematopoieticCD4+CD8+ thymocytes,
suggesting human MAIT cells are selected in a similar manner to
mouse MAIT cells (5). Unlike classically restricted thymocytes,
human MAIT thymocytes produce TNF and IFN-γ in response
to bacterially infected cells (4, 5). This thymically acquired func-
tional capacity is distinct from that of naïve classically restricted T
cells that require antigen-dependent activation in the periphery
followed by division and differentiation, a process that delays
acquisition of effector function.
While thymic MAIT cells have the functional capacity to serve
as “innate” effector T cells, their cell surface phenotype is similar to
that of a naïve T cell. Following thymic egress, MAIT cells in the
periphery expand and acquire a cell surface memory phenotype
indicative of antigen-experience (7). To this extent, human CD8+
TRAV1-2+ MAIT cells appear to be enriched within the CD8+
T cell subset of the blood compared to the thymus (4, 5, 17). These
data imply that while MAIT cells gain effector capacity in the
thymus, they proliferate and expand in the periphery, presumably
due to exposure to exogenous antigen.
Human MAIT Cell Phenotype in Peripheral
Blood and Tissues
Mucosal associated invariant T cells egress from the thymus
into the blood where they circulate the lymphatic system and
acquire an effector memory phenotype, indicated by cell sur-
face expression of CD45RA CD45RO+CD95hiCCR7 CD62Llo
(5, 18). MAIT cells are abundant in human blood and in a number
of tissues, including the small intestine, lungs, and liver (1, 7, 8, 18–
21). Indeed, MAIT cells received the name “mucosal-associated
invariant T cells” based on early data suggesting their enrichment
in the lamina propria of the small intestine (1). Although their
frequencies and role at mucosal tissues are largely unknown, these
data indicate that MAIT cells accumulate at sites where foreign
microbes have the potential to gain access to the body.
Human MAIT cells were originally defined as double negative
or CD8+ T cells that expressed TRAV1-2 mRNA transcripts by
PCR (12). However, given that classically restricted T cells and
CD4+ CD1b-restricted germline-encoded mycolyl lipid (GEM)
T cells also express TRAV1-2, TRAV1-2 expression alone is not
sufficient for the definition of a MAIT cell. MAIT cells can
also be characterized by high expression of the C-type lectin
receptor, CD161 (KLRB1) (2). Although the physiological func-
tion of CD161 is still not known, a recent study found that
TCR-dependent MAIT cell activation could be blocked by anti-
CD161 antibodies (22). Currently, the co-expression of CD161
and TRAV1-2 has been widely used to delineate MAIT cells
ex vivo (2).
TRAV1-2+CD161+ MAIT cells have been associated with
additional cell surface markers, including the IL-18R, the dipep-
tidyl peptidase-4 or CD26, the ABCB1 drug resistance transporter
(CD243), and the chemokine receptorsCCR6,CXCR6, andCCR5,
which are associatedwith trafficking to tissues including the intes-
tine and liver (2, 8, 18, 23). Furthermore, the transcription factor
PLZF (ZBTB16), which was previously associated with “innate”
effector function in CD1d-restricted iNKT cells in mice, has been
associated with MAIT cells in the thymus, blood, and tissues of
humans as early as the second trimester of gestation (2, 21, 24).
Following the discovery that MAIT cells were activated by
microbial ligands, MAIT cells have been identified in several
ways including function. FunctionalMAIT cells have beendefined
as CD8+ TRAV1-2+ T cells that produce the pro-inflammatory
cytokines, IFN-γ and TNF, in an MR1-dependent manner when
co-incubated with infected cells (6–8, 25). To overcome the limi-
tation that CD161 down-regulation can occur in activated MAIT
cells, a simple phenotypic panel for defining thoseMAIT cells with
the capacity to detect infected cells in the absence of ex vivo stim-
ulation was identified for MAIT cells from healthy human blood.
Sharma et al. demonstrated that all CD8+ TRAV1-2+ CD26hi T
cells could produce TNF in response to infected cells (25). MAIT
cells have also been reported to produce IL-17 in response to
TCR-independent stimulation (18). Therefore, while peripheral
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bloodMAIT cells with pro-inflammatory function can be defined
phenotypically as CD8+ or double negative TRAV1-2+ CD26hi
CD161hi T cells, the phenotype of tissue=derived MAIT cells, or
potentially functionally distinct MAIT cell subsets, remains to be
validated.
The elucidation of the crystal structure and identification of
small molecule ligands for MR1 have resulted in the generation
of a human MR1 tetramer (6, 19). The MR1 tetramer consists of
four molecules of biotinylated MR1, each presenting one MAIT
cell antigen (rRL-6-CH2OH or 5-OP-RU), and bound to four
molecules of fluorescently labeled streptavidin. In human blood
and small intestine, this tetramer identifies MAIT cells, as it binds
to virtually all TRAV1-2+ CD161hi T cells in a TCR-dependent
fashion (19). Using the human MR1 tetramer, a number of novel
observations have been made (19, 26). For example, Rentragoon
et al. have shown that TRAV1-2 can rearrange with TRAJ12 and
TRAJ20 in addition to TRAJ33, suggesting MAIT cell TCRs are
more diverse than originally thought (19). In addition, their data
suggest that a subset of CD3+ T cells binding the MR1 tetramer
haveminimal to no expression of CD161. These datamay indicate
that CD161 is not sufficient forMAIT cell identification. Thus, the
MR1 tetramer will allow for detection of MAIT cells regardless
of their ex vivo cell surface molecule expression or anti-microbial
function, facilitating an unbiased characterization of MAIT cells
in human health and disease.
MAIT Cells in Mice
Mouse MAIT cells, defined by expression of the invariant TCRα
chain TRAV1 TRAJ33 (Vα19Jα33), are present at very low fre-
quencies in wild-type C57BL/6 and BALB/c laboratory mouse
strains (1). Identification of MAIT cells in mice has been signif-
icantly hindered by the lack of a commercially available antibody
for the murine TCRα chain, TRAV1. NK1.1 was shown to be
expressed onmouseMAIT cells derived from transgenic C57BL/6
mice (27). However, NK1.1 is expressed on a limited number
of laboratory mouse strains, and therefore its utility in defining
MAIT cells is not clear. Due to the reagent limitations and the
relatively low frequency ofMAIT cells inmice, their identification
has been restricted to the isolation of double negative T cells via
fluorescence-activated cell sorting (FACS), followed by the quan-
tification of TRAV1 TRAJ33 transcripts (1). Nonetheless, several
in vivomouse studies have contributed valuable insight suggesting
a role for MAIT cells in the early immune response to respiratory
pathogens (10, 11). These studies will be discussed in detail below.
MAIT Cells have Considerable TCR
Diversity
While little is known about the TCR repertoire of MAIT cells
in the thymus, their repertoire in peripheral blood has been the
subject of several recent reports. These studies have shown that the
MAIT cell TCR repertoire in the periphery is more heterogeneous
than previously thought (19, 28, 29). Historically, MAIT cells
were defined by their expression of the TCRα chain TRAV1-2
adjoined to TRAJ33 and paired with a limited set of TCRβ chains
(TRBV6 and TRBV20) (13). This definition was further refined
based upon the finding of N-nucleotide additions within the Vα
and Jα (CDR3α) junctional region, lending to the modification
of their name from “invariant” to “semi-invariant” (26, 30). This
limited array of TCRα and β chains suggestedMAIT cells detected
a conserved antigen. However, more recently, several groups
have identified substantial diversity in TRAJ gene usage, TCRβ
chain pairing, and the CDR3α regions associated with TRAV1-
2 of MR1-restricted T cells (19, 28). Heterogeneity in TCR usage
suggests the possibility that MAIT cells recognize a more diverse
set of ligands.
MAIT Cells Recognize Microbe-Derived
Riboflavin Metabolites
Recently, the laboratories ofMcCluskey and Rossjohn successfully
identified small molecules derived from the folic acid (vitamin B9)
and riboflavin (vitamin B2) metabolic pathways as the first known
ligands for MR1(6). They determined that metabolites from the
riboflavin pathway, but not the folic acid pathway, activated Jurkat
T cells expressing the invariant TCRα chain TRAV1-2 paired
with TRBV6.1, TRBV6.4, or TRBV20. These data were intriguing
as previously the only known antigens for T cells consisted of
peptides, glycolipids, sphingolipids, and in mice short formylated
peptides (31). Thus, these data identified small molecules as a new
and unique class of T cell antigens.
Using culture supernatant from Salmonella typhimurium,
a microbe previously shown to activate MAIT cells, the
ribityllumazines, 6-hydroxymethyl-8-d-ribityllumazine (rRL-6-
CH2OH), 7-hydroxy-6-methyl-8-d-ribityllumazine (RL-6-Me-
7-OH), and 6,7-dimethyl-8-d-ribityllumazine (RL-6,7-diMe)
were found to bind MR1 and activate MAIT cells. Furthermore,
the molecule rRL-6-CH2OH proved to be the most efficient
at activating human MAIT cells. These data suggest that there
are multiple ligands for MR1 that may vary in their ability to
activate the MAIT TCR. In addition to ribityllumazines, a photo
degradation product of folic acid, 6-formyl pterin (6-FP), was
identified, bound to MR1’s ligand binding cavity in the first
crystal structures (6, 32). However, unlike riboflavin metabolites,
MR1-bound 6-FP was unable to activate MAIT cells. Given these
data, it is possible that molecules derived from other metabolic
pathways in addition to riboflavin and folic acid might provide
additional sources of MR1 ligands. Interestingly, although both
microbes and plants can produce folic acid and riboflavin,
only ribityllumazines have been shown to activate MAIT cells.
It remains to be determined if these exogenously produced
molecules represent the complete repertoire of MR1 ligands.
Recent studies have characterized additional MR1 ligands,
termed “neo-antigens” (33). Neo-antigens are small organic
molecules, generated by the modification of unstable riboflavin
metabolites by glyoxal/methylgyoxal, and are identified
as 5-(2-oxoethylideneamino)-6--ribitylaminouracil(5-OE-RU)
and 5-(2-oxopropylideneamino)-6--ribitylaminouracil(5-OP-
RU). These neo-antigens can bind MR1 and activate MAIT cells,
implying that in addition to the previously defined riboflavin
intermediates, molecular bi-products created from the interaction
between microbial- and potentially host-derived small organic
molecules may represent new antigens for MAIT cells. It remains
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possible that riboflavin metabolites and their physiological
bi-products differ between microbial species, providing a
plausible basis for MAIT cells to respond selectively to discrete
microbes. In support of this hypothesis, Gold et al., have found
selective microbe-associated TCR usage within an individual.
In brief, functional MAIT cells were isolated from four human
donors based on their response to Mycobacterium smegmatis, S.
typhimurium, or C. albicans (28). Evaluation of the MAIT cell
TCR repertoire of each individual demonstrated that there are
distinct TCR usages in response to the three different microbes.
These data suggest that MAIT cells could be selectively expanded
in response to distinct microbial ligands. The possibility that TCR
usage could be associated with selective ligand recognition was
confirmed by the finding that individual MAIT cell clones had
distinctive functional responses to two known ribityllumazine
antigens. MAIT cells may nevertheless expand in the periphery
due to ongoing exposure to exogenous antigen that may or may
not be associated with microbial infection. In sum, these data
suggest that individual MAIT TCRs can display ligand selectivity,
implying that, like classically restricted T cells, an individual’s
MAIT TCR repertoire may reflect previous or ongoing microbial
exposures.
While most microbes produce riboflavin, the process and
molecules involved in the metabolic pathway are markedly dif-
ferent between bacterial and yeast species (34). Some microbes
such asM. smegmatis and several Candida species are considered
“overproducers” of riboflavin (34). Thus, the ability of microbes
to produce riboflavin has been reported to fluctuate dramatically
depending on the availability of chemical elements, including, but
not limited to, iron, manganese, zinc, and magnesium (34). These
data indicate that the physiological levels of these molecules may
affect antigen production by the microbe. However, the mecha-
nisms by which many microbes individually regulate riboflavin
synthesis and how chemical elementsmay regulate these pathways
remain unknown. As a result, it remains an open question as
to whether or not MAIT cells with pathogen specificity can be
defined. Thus, one of the top priorities in the field of MAIT cell
immunobiology is the identification of these microbial antigens.
MR1 Structure
The structural elucidation of MR1 provided the first insight into
the nature of ligands presented by this molecule (6, 32). The
overall backbone structure of MR1 is most closely related to the
classical class I MHC, HLA-A2; however, the antigen-presenting
groove has a number of unique features. TheMR1 cavity is smaller
and has two pocket structures capable of binding small molecule
antigens (Figure 1A). The A0 pocket, named as such due to the
similarity in location to the A0 tunnels in CD1 molecules, is
lined with aromatic and basic residues, creating a small, positively
charged cavity that is almost entirely sequestered from external
solvent. An additional pocket, termed F0 (similar in location to the
F0 tunnel in CD1 molecules), is more shallow and can be variable
in size due to flexibility noted in the structure of the α2 helix
of human MR1(6). A comparison between the two molecules in
the asymmetric unit of the human structure revealed an ~11Å
shift between the positioning of the N-terminal portion of the
FIGURE 1 |Molecular basis of antigen presentation by MR1 and
recognition by MAIT TCRs. (A) Backbone (ribbon) and surface
representations of the structure of human MR1 (PDB ID: 4GUP) are shown in
cyan. In the MR1, A0 pocket is shown the 6-FP ligand in yellow, with nitrogen
atoms colored blue, and oxygen in red. The A0 and F0 pockets are labeled as
such. (B) MAIT TCR recognition of MR1 presenting the stimulatory antigen,
rRL (rRL-6-CH2OH) (PDB ID: 4LCC), only CDR loops of the MAIT TCR are
shown, positioned in complex with MR1. CDRa loops are colored pink; CDRb
are shown in blue. The rRL antigen is shown as above for 6-FP. In the insert is
a zoomed view of the CDR3a (Y95) and CDR3b (E99) loop interactions with
the ribtyl chain of rRL, showing the hydrogen-bonds as yellow dashes.
α2 helix, with one molecule having a significantly inward-shifted
helix resulting in a pseudo-collapsed F0 pocket. The structure of
the A0 pocket was almost identical between the two structures,
suggesting that this flexibility would not directly affect antigens
presented in this pocket, although this phenomenon may shed
light onto themolecularmechanisms of ligand loading. Curiously,
this conformational flexibility was not apparent in the structure of
bovine MR1 solved in complex with a MAIT TCR; either bovine
MR1 has greater rigidity in this region or complexation with a
TCR stabilizes this region of MR1(32).
In both crystal structures of MR1, electron density consistent
with a bound ligand in the A0 pocket was apparent. The protein
used in producing these crystals came from two different sources;
humanMR1 was refolded in the presence of RPMI culture media,
whereas bovine MR1 was secreted from insect cells. The ligand
from humanMR1 was characterized as 6-FP, a pterin-based com-
pound discussed previously. The electron density in bovine MR1
was similar to that identified in human MR1, consistent with a
pterin-like compound such as 6-FP. This compound is prevalent
in cell culture media, explaining its availability for forming com-
plexes with MR1. In both structures, the ligand electron density
was continuous with a lysine residue (K43) deep within the A0
pocket, supporting a covalent attachment of this compound via
Schiff base. While it has yet to be demonstrated whether 6-FP and
the covalent attachment are relevant in the normal functioning of
MR1 presentation in vivo, exogenous addition of this compound
leads to up-regulation of MR1 on the cell surface, yet does not
lead to, in fact can be antagonistic toward MAIT activation (6),
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suggesting it can stabilize MR1 but cannot provide a stimulatory
signal to MAIT cells through their TCR.
The elucidation of lumazine-based compounds, previously
described as MAIT cell antigens, is variants of ribityl-lumazine
compounds, which contain a two-ring core structure with a ribityl
extension. The ring structures are well-accommodated within the
aromatic environment of the A0 pocket and, depending on the
lumazine derivative, also establish hydrogen-bonding networks
with the basic residues located within this pocket. The ribityl
group extends from the A0 pocket and is engaged to differing
degrees depending on the orientation of the lumazine group, by
the MAIT TCR (30, 35). It is these additional ligand-mediated
contacts between the CDR3α and, depending on the sequence of
the MAIT TCR, CDR3β loops that enhance MAIT TCR binding
leading to MAIT cell activation (Figure 1B). Other derivatives
of intermediaries of the riboflavin pathway that are highly stim-
ulatory to MAIT cells, including the “neo-antigens” 5-OE-RU
and 5-OP-RU, are presented by MR1 via a covalent Schiff base
attachment (33). All characterized ligands for MR1 have been
shown to be presented through interactions, either covalent or
non-covalent, with residues lining the A0 pocket. Whether there
are other ligands for MR1, potentially being presented also in
the F0 pocket, is unclear at this time, although considering the
universe of ligand possibilities for this protein it is likely that there
are at least some non-B vitamin small molecules that derive from
endogenous or exogenous sources that can be presented by MR1.
Indeed, it is likely the B vitamin ligands identified thus far are
only a subset of the ligand repertoire presented by this intriguing
MHC-like protein and that there are other small molecule candi-
dates for activatingMAIT cells during microbial surveillance and,
potentially, other non-microbial related surveillance activities.
MR1-Dependent Antigen Processing and
Presentation
MR1 transcripts and protein are expressed ubiquitously in all
mammalian cells tested (36–38). However, unlike classical MHC
molecules, the MR1 protein resides primarily in intracellular
endocytic compartments, while cell surface expression is often
undetectable (39). One hypothesis is that MR1 is under tight
regulation as to avoid indiscriminate activation of MAIT cells. To
this extent, cells infected with Mtb, a pathogen known to elicit
MAIT cell responses, or cells treated with the newly identified
MR1 ligand, 6-FP, increased and stabilized expression of MR1 on
the cell surface (5, 40). These data suggest that the availabilityMR1
ligand(s) is requisite for MR1 surface expression and therefore
MAIT cell activation.
A recent study implies that in humans with dysregulated
immune systems, MAIT cell prevalence and activation were
associated with pathology (41). For example, MAIT cells were
enriched and activated, as determined by expression of Ki67,
NKG2D, and BTLA, in ileum tissue sections taken from humans
with inflammatory bowel disease compared to healthy control
subjects (41). Thus, careful regulation of MR1 expression may be
necessary in tissues such as the gut where exposure to microbes
is ubiquitous. Regulation of surface expression of MR1 appears
to be a limiting factor for MAIT cell activation, as stabilizing
endogenous MR1 cell surface expression ex vivo has the potential
to activate MAIT cells (42). At present, the mechanisms by which
antigens are processed and presented in the context of MR1 are
largely unknown.
MAIT Cells Play a Protective Role in
Antimicrobial Immunity
Le Bourhis et al. provided the first in vivo evidence suggesting
that MAIT cells were protective against bacterial pathogens (8).
In this study, TRAV1 (iVα19) and TRBV6 (Vβ6)-transgenic mice,
on an MR1-sufficient (MR1+/+) or an MR1-deficient (MR1 / )
background, the latter of which lack MAIT cells, were injected
intraperitoneally with E. coli or Mycobacterium absessus. In both
cases, MR1 /  mice had increased bacterial burden implicating
a role for MAIT cells in the protection against two different
microbes. In this same study, control C57BL/6 mice expressing
wild type levels ofMR1hadno significant change inmycobacterial
burden in comparison to MR1 /  mice. Notably, TRAV1- and
TRBV6-transgenic mice have increased numbers of MAIT cells
in comparison to wild type mice, indicating that the augmented
frequencies of MAIT cells in the transgenic mice resulted in pro-
tection (2). Following this study, several groups have found that
MAIT cells were associated with early protection against bacterial
pathogens in mouse models of infection, the details of which will
be discussed below.
Mycobacteria
In an effort to determine the role of MAIT cells in protection
against mycobacterial infections in vivo, Chua et al. challenged
MR1 /  mice with a low dose aerosol infection of Mycobac-
terium bovis BCG (10). MR1 /  mice had significantly increased
bacterial burden at day 10 following infection in comparison to
MR1+/+ mice. However, at day 30 post-infection, the bacterial
burden of MR1+/+ and MR1 /  mice were not significantly dif-
ferent. These data suggest that MAIT cells enhance early contain-
ment of mycobacterial infection in the lungs. Further studies are
needed to determine if MR1 /  mice infected with aerosolized
Mtb will recapitulate this phenotype.
In the same study, MAIT cells contributed to enhanced bac-
terial containment within macrophages in an MR1-independent
manner. Survival of BCG in macrophages was dramatically
reduced during an in vitro co-culture of enriched MAIT cells,
derived from the double negative, CD8+, andCD4+ T cell subsets
of TRAV1 transgenic mice. However, when a similar fraction
of cells from wild type mice (which contain very few MAIT
cells) were co-incubated with infected macrophages, no effect
on bacterial containment was noted. To determine if the anti-
mycobacterial capacity ofMAIT cells was dependent on activation
through MR1, MAIT cells were co-incubated with MR1 deficient
macrophages that were infected with BCG. Surprisingly, absence
of MR1 did not preclude MAIT cells from reducing intracellular
survival of BCG. To determine if IL-12 secretion by infected
macrophages was responsible for MAIT cell activity, a blocking
antibody to IL-12 was included in a co-incubation of MAIT
cells and infected macrophages. This experiment showed that in
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the absence of IL-12, MAIT cells lost their bactericidal capacity.
The authors suggest that MAIT cell activation and antibacterial
capacity were dependent on IL-12 and not MR1. However, the
contribution of IL-12 in vivo and the mechanism by which it
enhanced mycobacterial control were not directly demonstrated.
The possibility that MAIT cells can be activated in an MR1-
independent manner has been supported by the recent observa-
tion that IL-12 and IL-18 production by macrophages infected
with E. coli is sufficient to induce IFN-γ production by human
liver-derived MAIT cells following an overnight co-culture (20).
Given the ability of IFN-γ to augment IL-12 production, it is pos-
sible that IL-12 secretion could stimulate a positive feedback cycle
in which MAIT cell production of IFN-γ further amplifies the
production of IL-12, which in turn promotes further MAIT cell
activation. By contrast, the ability of human blood-derived MAIT
cells to produce IFN-γ in response tomycobacteria-infectedAPCs
has been shown to be MR1-dependent (7, 8).
Klebsiella
Georgel et al. evaluated the role of MAIT cells in MR1 /  mice
given a high dose (2 108/mouse) intraperitoneal infection with
the Gram-negative bacterium, K. pneumonia (9). In wild type
mice, K. pneumonia was cleared within the first 72 h of infec-
tion, whereas in MR1 /  mice, bacteria had spread from the
site of injection to several tissues including the lungs. Overall,
the MR1 /  mice had significantly increased mortality. These
data are in agreement with that obtained in the BCG challenge
model, in that mice lacking MAIT cells had delayed bacterial
clearance, suggesting MAIT cells facilitate the early recognition
and clearance of bacterial infection.
In the same model, MR1 /  mice showed equivalent protec-
tion to wild type mice when infected with other Gram-negative
species, including E. coli, Shigella dysenteriae, and Yersinia ente-
rocolitica. These data would suggest that MAIT cells are more
important for clearance of some bacterial pathogens but not oth-
ers. In this regard, it is important to note in this study each of the
bacterial strains were administered by intraperitoneal injection,
and therefore it remains possible that MAIT cells could facili-
tate bacterial containment of the same strains following mucosal
routes of infection. Here, we postulate that MAIT cells may have
anatomic localization that might favor their role in the respiratory
tract.
Francisella
In support of the hypothesis, Meierovics et al. evaluated the role
of MAIT cells in the host response to a low-dose intranasal
infection with the Gram-negative bacterium, live vaccine strain
of Francisella tularensis (LVS). In wild type mice, MAIT cells
were enriched in the lungs as early as 8 days and up until the
latest time point tested (18 days) post-infection. Furthermore, in
wild type mice, the frequency of MAIT cells increased in the
lung as the bacterial burden decreased, indicating an inverse
correlation between the frequency of MAIT cells and the bacte-
rial burden. Alternatively, at days 10–15 post infection, MR1 / 
mice had significantly higher bacterial burden, 1 106 CFU ver-
sus 1–5 105 CFU in wild type mice. Whereas it took wild type
mice ~17 days to clear the infection, it took MR1 /  mice five
additional days (~22 days). These findings support the hypothesis
that MAIT cells contribute to early control of LVS in mice.
Mucosal associated invariant cells in the lungs of mice infected
with LVS were pro-inflammatory as they produced IFN-γ, TNF,
and IL17A during both early and late infection. As described for
the intracellular containment of BCG, co-incubation of purified
MAIT cells with LVS-infected macrophages resulted in bacterial
growth inhibition in an IL-12-dependent manner. Together, these
data suggest that the increase inMAIT cell frequencies in response
to pulmonary LVS infections and early control of the bacteria
within the lungs is MR1-dependent, but that IL-12 plays a direct
role in the containment of intracellular infection.
A Role for MAIT Cells in Human
Antibacterial Immunity
Several studies have implicated MAIT cells in the recognition
and possible control of intracellular infection in humans. MAIT
cells are present in equal or greater numbers in the lungs of
healthy humans, compared to peripheral blood and lymph nodes
(7, 8). Thus, MAIT cells are physically positioned to serve as
sentinels in the detection of respiratory pathogens, such as Mtb,
in the lung. The plausibility of MAIT cells serving as sensors
of pulmonary infection with Mtb is supported the observation
that subjects with pulmonary TB have diminished MAIT cell
frequencies in the peripheral circulation (7, 8). These findings
could reflect a dynamic relationship where the number of MAIT
cells in peripheral blood is inversely correlated with the pres-
ence of Mtb in the lung. Here, we postulate that the presence of
mycobacterial antigen in the lungs results in trafficking to the
site of infection and possible expansion of antigen-selectiveMAIT
cells. The hypothesis that bacterial infection could result in the
egress of MAIT cells from the peripheral circulation is supported
by the observation that MAIT cell frequencies are diminished in
the blood of individuals with bacterial sepsis (43).
The observations made thus far in humans and mice can be
used to develop a model by which MAIT cells contribute to
the control of intracellular infection. This model is presented
in Figure 2 and possesses the following: (1) thymically derived
MAIT cells have inherent effector capacity, and by virtue of their
preferential residence in mucosal sites can serve as early sensors
of bacterial or fungal infection; (2) early recognition of an infected
cell could result in the direct control of intracellular infection
through the release of pro-inflammatory cytokines and or cyto-
toxic molecules; (3) early recognition of an infected cell could
promote the acquisition of Th1 immunity through the release
of IFN-γ which in turn promotes the production of IL-12 from
tissue-resident DCs; (4) IL-12 may play a special role both in the
promotion of Th1 immunity and augmentation of the MAIT cell
response; and (5) microbial exposure results in the expansion and
maintenance of MAIT cells that are selective for these pathogens.
Outstanding Questions
MAIT Cells in Autoimmunity
Mucosal associated invariant cells have been implicated in
autoimmunity and inflammatory disorders, including chronic
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FIGURE 2 | Possible mechanisms of MAIT cells in human antibacterial
immunity. MAIT cells with effector function egress from the thymus and
circulate through the blood and lymph as well as traffic to mucosal tissues,
including the lungs. Upon bacterial infection, a dendritic cell (or other
MR1-expressing cell) can activate MAIT cells by presentation of
bacterial-derived antigens on MR1 (MR1-Ag) to the MAIT TCR (TRAV1-2). MAIT
cells activated in an MR1-dependent manner may then (i) undergo clonal
expansion of antigen-specific MAIT cells in the lungs and thus aquire long-term
memory to specific pathogens, a hypothesis that still needs to be tested. (ii)
directly lyse cells infected with Mtb by secreting the cytotoxic molecules
granzyme and perforin (22, 25, 44), (iii) indirectly kill mycobacteria by secreting
the pro-inflammatory cytokines, TNF and IFN-γ, through recruitment and
activation of effector cells to the site of infection. MAIT cells may also be
activated, in an MR1-independent manner, by IL-12 produced by a local
infected macrophage. The activated MAIT cell may then secrete IFN-γ and
stimulate a positive feedback cycle in which IFN-γ augments expression of IL-12
by infected macrophages and vice versa. Furthermore, the abundance of IFN-γ
may then contribute to priming and maturation of naïve DCs that traffic to the
lymph node and initiate Th1 immunity. Thus, suggesting a possible scenario by
which MAIT cells may bridge innate and adaptive immunity.
inflammatory demyelinating polyneuropathy, experimental
autoimmune encephalomyelitis, multiple sclerosis, arthritis,
celiac disease, and as mentioned previously IBD (41, 45–50).
One hypothesis is that these autoimmune conditions could be
instigated or exacerbated by prior or ongoingmicrobial infections.
Here, we postulate that bacterially-derived MR1 ligands could
serve as “molecular mimics” of host-derived compounds allowing
for MAIT cell autoreactivity. In this context, the MAIT cell TCR
may recognize host-derived pterins or pterin-like small molecules
that may serve as ligands for MR1. Additionally, host-derived
molecules may bind MR1 and activate MAIT cells, or like 6FP,
serve to stabilize MR1.
It is also possible that MAIT cells may be activated in an MR1-
independent manner by pro-inflammatory cytokines as a result
of ongoing tissue inflammation. These activated MAIT cells may
then secrete pro-inflammatory cytokines or exert their cytolytic
potential in an indiscriminate manner. While MAIT cells have
been associated with autoimmunity, it remains unknown if they
serve a pathological role in these diseases. It is also possible that
they play a protective or regulatory role. With the advent of the
MR1 tetramer and the development of comprehensive ex vivo
functional assessment, the physiological function of these cells in
autoimmunity can be further elucidated.
The Role of MAIT Cells in Vaccination
Vaccines serve to initiate long-term protection through induc-
tion of adaptive immunity. Currently available vaccines are often
administered systemically, and hence may be less effective in the
initiation andmaintenance of mucosal immunity. The desirability
of mucosal vaccinationmight be particularly evident in infections
that are spread via aerosol (51). In this regard, the role that MAIT
cells might play in a mucosal vaccine is largely unexplored. One
possibility is that MAIT cell expansions in the lung do not reflect
long-termmemory but depend on the ongoing presence ofmicro-
bial ligand. In this regard, it might be envisioned that MAIT cells
could be harnessed as “adjuvants” inmucosally delivered vaccines.
Alternately, if MAIT cells have memory, then vaccination with
selective ligands could result in the stable expansion ofMAIT cells.
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Could MAIT Cells Be Used as Mucosal
Adjuvants?
Given that conventional systemic vaccines rely on the presence of
an adjuvant to elicit sustained B cell and T cell responses, we pos-
tulate that the activation of MAIT cells in the lung could serve to
facilitate the acquisition of adaptive immunity. At present, FDA-
approved adjuvants are TLR agonists.While these are traditionally
thought to result in the direct activation of APCs such as DCs,
we postulate that the activation of lung-resident MAIT cells could
promote the acquisition of Th1 immunity, and hence could serve
as an adjuvant.With the recent discovery of vitamin Bmetabolites
serving asMAIT cell antigens, one could envision ribityllumazines
as a class of “Vita-PAMPS,” that if safely delivered to the mucosal
surface where MAIT cells are present, could serve as a mucosal
adjuvant (52).
Could MAIT Cells Be Targeted for a Mucosal
Vaccine?
Alternately, we speculate that the expansion and maintenance
of microbial selective MAIT cells could be used as a mucosal
vaccination strategy. These approaches will depend on the iden-
tification of microbial-selective ligands, their stable formulation,
and their delivery either systemically or via aerosol. While either
the adjuvant or vaccination strategies are attractive, significant
challenges remain. First, antigens that are selective for discrete
pathogens, such as Mtb, remain to be identified. Second, many of
the ligands identified to date are unstable, making them unsuit-
able for vaccination studies. Third, animal models that reflect
a human MAIT cell immunobiology have not been developed.
In this regard, a mouse model would be ideal, and will likely
require the identification of mouse strains that have MAIT cell
frequencies and reactivity that are similar to humans. Alternately,
it is possible that other animal species, such as the rabbit, guinea
pig, or non-human primates, may be needed.
Concluding Remarks
While existing data strongly support a role for MAITs in the
recognition and control of microbial infection, particularly at
the mucosal surface, there remains much that is not known.
For humans, a direct demonstration of the role of MAIT cells
in the host response to microbial infection will either require
the identification of MR1 variants that alter MAIT cell function,
and potentially increase the host-vulnerability to infection, or the
identification of altered developmental pathways that alter MAIT
cell frequency and function. In this regard, it might be expected
that these deficiencies affect other cell types, such as iNKT cells.
Alternately, vaccination strategies that harness MAIT cells would
also allow formore direct demonstration of the protective capacity
of MAIT cells. Finally, given the tight regulation of MR1 surface
expression and MAIT cell activation, it is possible that microbial
activation of MAIT cells could have the unintended consequence
of promoting autoimmunity.
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